Aridis Pharmaceuticals, Inc. (ARDS)
USD 0.0
(0.0%)
USD 0.0
(0.0%)
| Year | Total Assets | Total Assets Growth |
|---|---|---|
| 2022 | 14.69 Million USD | -45.16% |
| 2021 | 26.79 Million USD | 77.26% |
| 2020 | 15.11 Million USD | -45.95% |
| 2019 | 27.96 Million USD | -11.53% |
| 2018 | 31.61 Million USD | 19.39% |
| 2017 | 26.47 Million USD | 17.49% |
| 2016 | 22.53 Million USD | 0.0% |
| Year | Total Assets | Total Assets Growth |
|---|---|---|
| 2023 Q1 | 9.43 Million USD | -35.8% |
| 2023 Q3 | 6.53 Million USD | 0.8% |
| 2023 Q2 | 6.48 Million USD | -31.29% |
| 2022 FY | 14.69 Million USD | -45.16% |
| 2022 Q3 | 12.12 Million USD | -27.36% |
| 2022 Q4 | 14.69 Million USD | 21.25% |
| 2022 Q1 | 23.81 Million USD | -11.12% |
| 2022 Q2 | 16.68 Million USD | -29.94% |
| 2021 Q2 | 11.38 Million USD | -35.19% |
| 2021 FY | 26.79 Million USD | 77.26% |
| 2021 Q3 | 26.08 Million USD | 129.08% |
| 2021 Q4 | 26.79 Million USD | 2.73% |
| 2021 Q1 | 17.56 Million USD | 16.22% |
| 2020 Q4 | 15.11 Million USD | 24.87% |
| 2020 Q3 | 12.1 Million USD | -33.17% |
| 2020 Q2 | 18.11 Million USD | -17.69% |
| 2020 Q1 | 22 Million USD | -21.31% |
| 2020 FY | 15.11 Million USD | -45.95% |
| 2019 FY | 27.96 Million USD | -11.53% |
| 2019 Q4 | 27.96 Million USD | -18.62% |
| 2019 Q3 | 34.36 Million USD | 116.5% |
| 2019 Q2 | 15.87 Million USD | -31.72% |
| 2019 Q1 | 23.25 Million USD | -26.45% |
| 2018 Q2 | 16.09 Million USD | -28.75% |
| 2018 FY | 31.61 Million USD | 19.39% |
| 2018 Q4 | 31.61 Million USD | -18.05% |
| 2018 Q3 | 38.57 Million USD | 139.64% |
| 2018 Q1 | 22.59 Million USD | -14.68% |
| 2017 Q4 | 26.47 Million USD | 0.0% |
| 2017 FY | 26.47 Million USD | 17.49% |
| 2016 FY | 22.53 Million USD | 0.0% |
| Name | Total Assets | Total Assets Difference |
|---|---|---|
| America Great Health | 299.12 Thousand USD | -4812.596% |
| Ampio Pharmaceuticals, Inc. | 5.73 Million USD | -156.189% |
| Biora Therapeutics, Inc. | 31.21 Million USD | 52.923% |
| Bio-Path Holdings, Inc. | 3.22 Million USD | -356.366% |
| Better Therapeutics, Inc. | 22.94 Million USD | 35.95% |
| Calithera Biosciences, Inc. | 28.67 Million USD | 48.755% |
| Comera Life Sciences Holdings, Inc. | 3.72 Million USD | -294.273% |
| Gene Biotherapeutics, Inc. | - USD | -Infinity% |
| eFFECTOR Therapeutics, Inc. | 20.54 Million USD | 28.471% |
| Eloxx Pharmaceuticals, Inc. | 21.12 Million USD | 30.431% |
| Evelo Biosciences, Inc. | 64.44 Million USD | 77.196% |
| Evolutionary Genomics, Inc. | 2.35 Million USD | -524.333% |
| Finch Therapeutics Group, Inc. | 70.99 Million USD | 79.302% |
| Galera Therapeutics, Inc. | 26.14 Million USD | 43.786% |
| Innovation1 Biotech Inc. | 75.99 Thousand USD | -19237.307% |
| Kiromic BioPharma, Inc. | 12.16 Million USD | -20.758% |
| Molecular Templates, Inc. | 35.38 Million USD | 58.469% |
| Navidea Biopharmaceuticals, Inc. | 4.37 Million USD | -236.146% |
| NexImmune, Inc. | 8.59 Million USD | -70.992% |
| Orgenesis Inc. | 14.55 Million USD | -0.983% |
| Panbela Therapeutics, Inc. | 11.8 Million USD | -24.513% |
| Point of Care Nano-Technology, Inc. | 124.64 Thousand USD | -11689.671% |
| PaxMedica, Inc. Common Stock | 5.68 Million USD | -158.696% |
| Scopus BioPharma Inc. | 392.26 Thousand USD | -3646.192% |
| Sorrento Therapeutics, Inc. | 472.84 Million USD | 96.892% |
| Statera Biopharma, Inc. | 21.16 Million USD | 30.585% |
| TRACON Pharmaceuticals, Inc. | 10.1 Million USD | -45.423% |
| Trevena, Inc. | 40.6 Million USD | 63.81% |
| Vaxxinity, Inc. | 44.35 Million USD | 66.868% |
| Vaccinex, Inc. | 3.63 Million USD | -304.709% |
| Vicapsys Life Sciences, Inc. | 39.65 Thousand USD | -36956.183% |
| Viracta Therapeutics, Inc. | 56.69 Million USD | 74.079% |
| ZIVO Bioscience, Inc. | 555.71 Thousand USD | -2544.341% |